# US 2021/0340574 A1 · Compositions and methods for genetic manipulation of methanotrophs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340574 A1
- Document ID: US20210340574A1
- Status: Published application
- Kind: A1
- Application number: 17/095,644
- Filed: 2020-11-11
- Published: 2021-11-04
- Earliest claimed: 2019-11-22
- Applicants: Calysta, Inc.
- Inventors: Jeremy Minshull; Jana Stumpe; Sonny Zhang; Megan Hsi
- Web page: https://patentgrep.com/patent/US20210340574A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/902: {using homologous recombination}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides compositions and methods for the genetic manipulation of methanotrophs utilizing a site-specific polynucleotide modification system.

## Claims

### Claim 1

A method of altering the genome of a methanotrophic bacterium, comprising culturing under conditions and for a time sufficient to allow expression in a methanotrophic bacterium of a site-specific polynucleotide modification system;
wherein the methanotrophic bacterium contains a heterologous nucleic acid molecule encoding the site-specific polynucleotide modification system that is operably linked to a regulatory element in a vector, the nucleic acid molecule comprising:
(a) a first heterologous nucleic acid molecule encoding a modification polypeptide, wherein the modification polypeptide comprises a targeting RNA binding domain and a site-specific nuclease domain, and
(b) a second heterologous nucleic acid molecule encoding a targeting RNA, wherein the targeting RNA comprises a duplex-forming region and a DNA-targeting domain,
wherein the complex of the expressed modification polypeptide with the expressed targeting RNA binds to and cleaves a genomic target sequence of the methanotrophic bacterium,
thereby site-specifically altering the genome of the methanotrophic bacterium.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
(a) the first heterologous nucleic acid molecule encoding the modification polypeptide encodes a Cas9 polypeptide;
(b) the first heterologous nucleic acid molecule encoding the modification polypeptide encodes a Cas9 polypeptide and is codon optimized for methanotrophic bacteria;
(c) the first heterologous nucleic acid molecule encoding the modification polypeptide encodes a Cas9 polypeptide and is codon optimized for Methylococcus capsulatus Bath or Methylosinus trichosporium OB3b;
(d) the first heterologous nucleic acid molecule comprises a polynucleotide sequence encoding a polypeptide having at least 80% sequence identity to SEQ ID NO:1; or
(e) the first heterologous nucleic acid molecule encoding the modification polypeptide encodes a Cas9 polypeptide having at least 80% identity to a polypeptide corresponding to Cas9 of Streptococcus pyogenes.

### Claim at position 3

-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the targeting RNA comprises:
(a) a crRNA comprising a DNA-targeting domain and a duplex-forming region; or
(b) an sgRNA.

### Claim 8 (depends on 7)

The method of claim 7, wherein the targeting RNA comprises a crRNA comprising a DNA-targeting domain and a duplex-forming region, and further comprising introducing into the methanotrophic bacterium a nucleic acid molecule encoding a tracrRNA comprising a duplex-forming region complementary to the duplex-forming region of the crRNA.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein:
(a) the second heterologous nucleic acid molecule encoding the targeting RNA further encodes a self-cleaving ribozyme located at the 5′-end, 3′-end, or both ends of the targeting RNA; and/or
(b) the second heterologous nucleic acid molecule encoding the targeting RNA further comprises a transcriptional terminator.

### Claim 11 (depends on 10)

The method of claim 10, wherein:
(a) the self-cleaving ribozyme comprises a polynucleotide sequence corresponding to SEQ ID NO:8 or SEQ ID NO:9; and/or
(b) the transcriptional terminator comprises a polynucleotide sequence corresponding to any one of SEQ ID NOS:7 and 13-17.

### Claim at position 9

-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the cleaved genomic target sequence is repaired by non-homologous end joining, by homology-directed repair, or a combination thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the methanotrophic bacterium further contains a third heterologous nucleic acid molecule comprising an integration polynucleotide, wherein the integration polynucleotide:
(a) comprises a 5′-homology flank comprised of at least about 20 nucleotides and a 3′-homology flank comprised of at least about 20 nucleotides'
(b) genetically modifies a gene of the methanotrophic bacterium;
(c) genetically modifies a regulatory element of the methanotrophic bacterium;
(d) introduces a point mutation, frameshift mutation, deletion, substitution, insertion, or any combination thereof;
(e) comprises a donor molecule;
(f) comprises a selectable marker;
(g) is contained in a vector; or any combination thereof.

### Claim at position 12

-20. (canceled)

### Claim 21 (depends on 15)

The method of claim 15, wherein the integration polynucleotide comprises a donor molecule comprising:
(a) a nucleic acid molecule encoding a heterologous protein; or
(b) a nucleic acid molecule encoding a homologous or endogenous methanotrophic bacterial protein.

### Claim 22 (depends on 21)

The method of claim 21, wherein the integration polynucleotide comprises a donor molecule encoding encoded a heterologous protein, wherein the heterologous protein is:
(a) a reporter protein
(b) an amino acid biosynthesis enzyme;
(c) an isoprene synthase, crotonase, crotonyl CoA thioesterase, 4-oxalocrotonate decarboxylase, or any combination thereof;
(d) a fatty acid converting enzyme;
(e) a fatty acid elongation pathway enzyme;
(f) a carbohydrate biosynthesis enzyme; or
(g) a lactate dehydrogenase.

### Claim at position 15

-27. (canceled)

### Claim 28 (depends on 15)

The method of claim 15, wherein the integration polynucleotide is contained in a vector and wherein:
(a) the integration polynucleotide further comprises a 5′-target sequence, a 3′-target sequence, and a PAM sequence, wherein the 5′-target and 3′-target sequences are targeted by the targeting RNA and the PAM sequence is targeted by the modification polypeptide;
(b) the vector comprises a counter-selectable marker; or
(c) the vector comprises a temperature sensitive origin of replication or an orioin of replication that is non-functional in the methanotrophic bacterium.

### Claim at position 17

-30. (canceled)

### Claim 31 (depends on 15)

The method of claim 15, wherein the methanotrophic bacterium further contains a fourth heterologous nucleic acid molecule encoding a recombinase.

### Claim 32 (depends on 31)

The method of claim 31, wherein the recombinase comprises lambda recombinase Exo, Bet, Gam, or any combination thereof, RecA recombinase, or Rac recombinase RecE, RecT, or both RecE and RecT.

### Claim 33 (depends on 1)

The method of claim 1, wherein the first heterologous nucleic acid molecule and the second heterologous nucleic acid molecule are contained in the same vector or in different vectors.

### Claim 34

(canceled)

### Claim 35 (depends on 31)

The method of claim 31, wherein:
(a) the first heterologous nucleic acid molecule, the second heterologous nucleic acid molecule, and the fourth heterologous nucleic acid molecule are contained in the same vector; or
(b) the first heterologous nucleic acid molecule encoding the modification polypeptide and the second heterologous nucleic acid molecule encoding the targeting RNA are contained in different vectors and at least one vector further comprises the fourth heterologous nucleic acid molecule.

### Claim 36

(canceled)

### Claim 37 (depends on 31)

The method of claim 31 wherein:
(a) the first heterologous nucleic acid molecule and the fourth heterologous nucleic acid molecule are arranged in a polycistronic operon; and/or
(b) the first heterologous nucleic acid molecule and the fourth heterologous nucleic acid molecule are operably linked to the same regulatory element.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

The method of claim 1, wherein:
(a) the first heterologous nucleic acid molecule and the second heterologous nucleic acid molecule are operably linked to the same regulatory element; or
(b) the first heterologous nucleic acid molecule and the second heterologous nucleic acid molecule are operably linked to different regulatory elements.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

The method of claim 1, wherein any one of the regulatory elements comprise:
(a) a host promoter, an exogenous promoter, or a non-natural promoter; and/or
(b) an inducible promoter.

### Claim at position 29

-44. (vanceled)

### Claim 45 (depends on 1)

The method of claim 1, wherein the methanotrophic bacterium is:
(a) a Methylococcus, Methylomonas, Methylomicrobium, Methylobacter, Methylocaldum, Methylovulum, Methylomarinum, Methylocystis, or Methylosinus; or
(b) a Methylococcus capsulatus Bath. Methylosinus trichosporium OB3b, Methylomonas 16a, Methylosinus sporium, Methylocystis parvus, Methylomonas methanica, Methylomonas albus, Methylobacter capsulatus, Methylobacterium organophilun, Methylomonas sp AJ-3670, Methylocella silvestris, Methylocella palustris, Methylocella tundrae, Methylocystis daltona SB2, Methylocystis bryophila, Methylocapsa aurea KYG, Methylacidiphilum infernorum, Methylibium petroleiphilum, or Methylomicrobium alcaliphilum.

### Claim at position 31

-47. (canceled)

### Claim 48

A modified methanotrophic bacterium, comprising a heterologous nucleic acid molecule encoding a site-specific polynucleotide modification system that is operably linked to a regulatory element in a vector, the nucleic acid molecule comprising:
(a) a first heterologous nucleic acid molecule encoding a modification polypeptide, wherein the modification polypeptide comprises a targeting RNA binding domain and a site-specific nuclease domain,
(b) a second heterologous nucleic acid molecule encoding a targeting RNA, wherein the targeting RNA comprises a duplex-forming region and a DNA-targeting domain, and
(c) a third heterologous nucleic acid molecule comprising an integration polynucleotide,
wherein the expressed modification polypeptide can associate with the expressed targeting RNA to form a complex capable of binding to and cleaving a genomic target sequence of the methanotrophic bacterium.

### Claim at position 33

-93. (canceled)
